Sanofi along with its global business unit Sanofi Genzyme’s investigational drug, Lemtrada (alemtuzumab) completed six plus years of extension study …

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in Drug Trials

Drug Trials

New Therapies Getting Ready to Challenge Vertex’s Established Cystic Fibrosis Drugs

Cystic fibrosis is a rare, severe genetic disorder that affects the lungs and the digestive system. A person having cystic ...

Drug Trials

Alynam’s Innovative Drug Reverses Rare Fatal Genetic Disease

RNA interference (RNAi) is a natural process in biology which switches off the faulty genes in the body to stop ...

Drug Trials

Highly Promising Multiple Sclerosis Drugs Lined Up for 2018

Historic approval of the first game-changing multiple sclerosis drug, Ocrevus in the first quarter of the year provided many companies ...

Drug Trials

Groundbreaking Oral Tablet Flu Vaccine Shows Promising Results

First oral tablet vaccine to prevent influenza (flu) virus showed a similar level of protection against the virus as imparted ...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...


Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply